Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Qiagen ( (QGEN) ) just unveiled an announcement.
Qiagen N.V. announced a managerial transaction involving Elaine Mardis, a member of its administrative body, following its synthetic share repurchase plan. As per the repurchase terms approved in June 2024, every 36 issued Qiagen shares were consolidated into 35 shares, affecting Mardis’ holding, which was reduced by 114 shares to total 3,973 shares. This transaction, not quantifiable in price or volume, took place outside a trading venue and reflects the company’s strategic financial adjustments.
More about Qiagen
Qiagen N.V. operates in the biotechnology sector, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its expertise in enabling advanced molecular testing and has a significant presence in both the healthcare and research markets.
YTD Price Performance: -0.02%
Average Trading Volume: 949,621
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.69B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.
